---
input_text: 'Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients
  With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. IMPORTANCE:
  Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia
  telangiectasia and Rad3 (ATR) may enhance the cytotoxicity of cisplatin, gemcitabine,
  and other chemotherapeutic agents. Cisplatin with gemcitabine remains the standard
  up-front therapy for treatment in patients with metastatic urothelial cancer. OBJECTIVE:
  To determine whether the use of the selective ATR inhibitor, berzosertib, could
  augment the activity of cisplatin with gemcitabine. DESIGN, SETTING, AND PARTICIPANTS:
  In a phase 2 randomized clinical trial, 87 patients across 23 centers in the National
  Cancer Institute Experimental Therapeutics Clinical Trials Network were randomized
  to receive either cisplatin with gemcitabine alone (control arm) or cisplatin with
  gemcitabine plus berzosertib (experimental arm). Key eligibility criteria included
  confirmed metastatic urothelial cancer, no prior cytotoxic therapy for metastatic
  disease, 12 months or more since perioperative therapy, and eligibility for cisplatin
  receipt based on standard criteria. The study was conducted from January 27, 2017,
  to December 15, 2020. INTERVENTIONS: In the control arm, cisplatin, 70 mg/m2, was
  given on day 1 and gemcitabine, 1000 mg/m2, was given on days 1 and 8 of a 21-day
  cycle. In the experimental arm, cisplatin, 60 mg/m2, was given on day 1; gemcitabine,
  875 mg/m2, on days 1 and 8; and berzosertib, 90 mg/m2, on days 2 and 9 of a 21-day
  cycle. MAIN OUTCOMES AND MEASURES: The primary end point of the study was progression-free
  survival. The analysis was on all patients who started therapy. RESULTS: Of the
  total of 87 patients randomized, 41 patients received cisplatin with gemcitabine
  alone and 46 received cisplatin with gemcitabine plus berzosertib. Median age was
  67 (range, 32-84) years, and 68 patients (78%) were men. Median progression-free
  survival was 8.0 months for both arms (Bajorin risk-adjusted hazard ratio, 1.22;
  95% CI, 0.72-2.08). Median overall survival was shorter with cisplatin with gemcitabine
  plus berzosertib compared with cisplatin with gemcitabine alone (14.4 vs 19.8 months;
  Bajorin risk-adjusted hazard ratio, 1.42; 95% CI, 0.76-2.68). Higher rates of grade
  3 vs grade 4 thrombocytopenia (59% vs 39%) and neutropenia (37% vs 27%) were observed
  with cisplatin with gemcitabine and berzosertib compared with cisplatin with gemcitabine
  alone; consequently, more dose reductions were needed in the experimental arm. Patients
  in the experimental arm received a median cisplatin dose of 250 mg/m2, which was
  significantly lower than the median dose of 370 mg/m2 in the control arm (P < .001).
  CONCLUSIONS AND RELEVANCE: The addition of berzosertib to cisplatin with gemcitabine
  did not prolong progression-free survival relative to cisplatin with gemcitabine
  alone in patients with metastatic urothelial cancer, and a trend toward inferior
  survival was observed with this combination. Berzosertib plus cisplatin with gemcitabine
  was associated with significantly higher hematologic toxicities despite attenuated
  dosing of cisplatin with gemcitabine. TRIAL REGISTRATION: ClinicalTrials.gov Identifier:
  NCT02567409.'
raw_completion_output: |-
  primary_disease: metastatic urothelial cancer
  medical_actions: administration of cisplatin;administration of gemcitabine;administration of berzosertib;dose reduction
  symptoms: progression of cancer;thrombocytopenia;neutropenia
  chemicals: Cisplatin;Gemcitabine;Berzosertib
  action_annotation_relationships: administration of cisplatin TREATS progression of cancer IN metastatic urothelial cancer;administration of gemcitabine TREATS progression of cancer IN metastatic urothelial cancer;administration of berzosertib (with Cisplatin and Gemcitabine) TREATS progression of cancer IN metastatic urothelial cancer;administration of cisplatin and gemcitabine PLUS berzosertib PREVENTS progression of cancer IN metastatic urothelial cancer;dose reduction PREVENTS thrombocytopenia IN metastatic urothelial cancer;dose reduction PREVENTS neutropenia IN metastatic urothelial cancer
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  dose reduction PREVENTS neutropenia IN metastatic urothelial cancer

  ===

extracted_object:
  primary_disease: metastatic urothelial cancer
  medical_actions:
    - administration of cisplatin
    - administration of gemcitabine
    - administration of berzosertib
    - dose reduction
  symptoms:
    - progression of cancer
    - HP:0001873
    - HP:0001875
  chemicals:
    - CHEBI:27899
    - CHEBI:175901
    - Berzosertib
  action_annotation_relationships:
    - subject: administration of cisplatin
      predicate: TREATS
      object: progression of cancer
      qualifier: metastatic urothelial cancer
      subject_extension: CHEBI:27899
    - subject: administration of gemcitabine
      predicate: TREATS
      object: progression of cancer
      qualifier: metastatic urothelial cancer
      object_qualifier: IN
      subject_extension: CHEBI:175901
    - subject: administration
      predicate: TREATS
      object: progression of cancer
      qualifier: metastatic urothelial cancer
      subject_qualifier: with Cisplatin and Gemcitabine
      subject_extension: berzosertib
    - subject: administration
      predicate: PREVENTS
      object: progression of cancer
      qualifier: metastatic urothelial cancer
      subject_extension: cisplatin and gemcitabine PLUS berzosertib
    - subject: dose reduction
      predicate: PREVENTS
      object: HP:0001873
      qualifier: metastatic urothelial cancer
    - subject: dose reduction
      predicate: PREVENTS
      object: HP:0001875
      qualifier: metastatic urothelial cancer
named_entities:
  - id: MONDO:0005086
    label: Renal cell carcinoma
  - id: MONDO:0003060
    label: Biliary tract cancer (BTC)
  - id: CHEBI:175901
    label: Gemcitabine
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0008840
    label: Ataxia Telangiectasia
  - id: MAXO:0010030
    label: Bone Marrow Transplantation
  - id: MAXO:0001001
    label: Gene Therapy
  - id: CHEBI:166830
    label: Acetyl-DL-leucine
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:4462
    label: Dexamethasone sodium phosphate
  - id: CHEBI:133021
    label: venetoclax
  - id: HP:0002721
    label: Immunodeficiency
  - id: HP:0002073
    label: progressive cerebellar ataxia
  - id: HP:0002013
    label: vomiting
  - id: HP:0002315
    label: headache
  - id: CHEBI:27899
    label: cisplatin
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001875
    label: Neutropenia
  - id: CHEBI:231342
    label: Ceralasertib
  - id: CHEBI:31355
    label: Carboplatin
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MONDO:0005184
    label: Pancreatic ductal adenocarcinoma (PDAC)
  - id: HP:0020174
    label: Drug resistance
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0010150
    label: Head and neck squamous cell carcinomas (HNSCC)
  - id: MAXO:0000014
    label: Radiotherapy (RT)
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0002015
    label: Dysphagia
  - id: MONDO:0008876
    label: Bloom Syndrome (BS)
  - id: HP:0001510
    label: growth retardation
  - id: HP:0011793
    label: malignancies
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: CHEBI:27656
    label: Camptothecin (CPT)
  - id: CHEBI:63632
    label: Topotecan
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:231344
    label: Talazoparib
  - id: CHEBI:231616
    label: M4344
  - id: MONDO:0008433
    label: Small-cell lung cancer (SCLC)
  - id: HP:0030357
    label: Small-cell lung cancer (SCLC)
  - id: MONDO:0003778
    label: Inborn Errors of Immunity (IEI)
  - id: HP:0033141
    label: Severe SARS-CoV-2 infection
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:22907
    label: Bleomycin (BLM)
  - id: MONDO:0005494
    label: Triple-negative breast cancer (TNBC)
  - id: CHEBI:9555
    label: 6-thioguanine
  - id: CHEBI:4659
    label: Disulfiram
  - id: CHEBI:28694
    label: Cu
  - id: CHEBI:83766
    label: Olaparib
  - id: HP:0002894
    label: pancreatic cancer
  - id: MONDO:0005192
    label: Pancreatic Cancer
  - id: MONDO:0007254
    label: Breast Cancer
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0003002
    label: Breast Cancer
  - id: MONDO:0008903
    label: lung cancer
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0005070
    label: Tumors
  - id: MAXO:0001394
    label: Oral administration
  - id: MONDO:0036501
    label: Refractory Cancer
  - id: CHEBI:45863
    label: Paclitaxel
  - id: MONDO:0018177
    label: Glioblastoma
  - id: MAXO:0000004
    label: Surgery
  - id: HP:0012174
    label: Glioblastoma
  - id: MONDO:0009807
    label: Osteosarcoma
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:132992
    label: radiosensitizers
  - id: MONDO:0005575
    label: colorectal cancer
  - id: CHEBI:62913
    label: poly (ADP-ribose) polymerase (PARP) inhibitors
  - id: HP:0010310
    label: Chylothorax
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:27563
    label: Arsenic
  - id: CHEBI:229924
    label: pifithrin-alpha (PFTalpha)
  - id: CHEBI:29678
    label: Sodium arsenite (NaAsO2)
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MONDO:0004986
    label: Bladder cancer
  - id: HP:0009725
    label: Bladder cancer
  - id: MONDO:0968974
    label: Large B-Cell Lymphoma (LBCL)
  - id: MAXO:0000381
    label: Lymph node biopsy
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:8382
    label: Prednisone
  - id: MONDO:0005623
    label: AT (Autoimmune Thyroiditis)
  - id: MONDO:0008315
    label: Prostate Cancer
  - id: CHEBI:4672
    label: Docetaxel
  - id: HP:0012125
    label: Prostate Cancer
  - id: CHEBI:50914
    label: PI3K inhibitors
  - id: CHEBI:34936
    label: di-phenoxy acetamide (DPA) analogs
  - id: CHEBI:25555
    label: Compound DPA (7n)
  - id: HP:0000988
    label: rash
  - id: CHEBI:31348
    label: capecitabine
  - id: CHEBI:16044
    label: MET
  - id: HP:0100526
    label: Lung cancer
  - id: MONDO:0019600
    label: Xeroderma pigmentosum (XP)
  - id: CHEBI:131808
    label: Thymidine dimers
  - id: CHEBI:28300
    label: Glutamine
  - id: CHEBI:16856
    label: Glutathione
  - id: CHEBI:16810
    label: Alpha-ketoglutarate
  - id: HP:0000657
    label: Oculomotor apraxia
  - id: HP:0001266
    label: Choreoathetosis
  - id: CHEBI:4806
    label: Epigallocatechin-3-gallate (EGCG)
  - id: CHEBI:16240
    label: H2O2
  - id: CHEBI:229722
    label: RP-3500
  - id: CHEBI:135702
    label: Belotecan
  - id: CHEBI:229661
    label: Omaveloxolone
  - id: CHEBI:8863
    label: riluzole
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0005140
    label: Epithelial ovarian cancer
  - id: HP:0002018
    label: Nausea
  - id: HP:0012378
    label: Fatigue
  - id: HP:0002039
    label: Anorexia
  - id: MONDO:0005233
    label: Non-small cell lung cancer
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: CHEBI:3077
    label: Betamethasone
  - id: CHEBI:30884
    label: Glucocorticoids (GCs)
  - id: MONDO:0024331
    label: Colorectal Cancer (CRC)
  - id: MONDO:0005061
    label: Lung adenocarcinoma (LUAD)
  - id: HP:0030078
    label: Lung adenocarcinoma
  - id: HP:0025318
    label: epithelial ovarian cancer
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: CHEBI:80630
    label: Irinotecan
  - id: CHEBI:131509
    label: lysine-specific histone demethylase 1a inhibitors
  - id: MONDO:0017361
    label: Chronic restraint stress (CRS)
  - id: CHEBI:16865
    label: GABA
  - id: MONDO:0006047
    label: Pancreatic Adenocarcinoma
  - id: CHEBI:76649
    label: Astaxanthin (AST)
  - id: CHEBI:40968
    label: Astaxanthin
